Since SP-C is a marker for alveolar type II cells [28, 33], the promoter for this gene was used for transgenic over-expression of SCGB3A2 in the alveolar areas because in a previous study using the BLM-induced pulmonary fibrosis model, pulmonary fibrosis was reduced by intravenous administration of SCGB3A2 [16, 24]. Here, SFTPC is linked to pulmonary fibrosis.